Leukemia, Chronic Clinical Trials

1 recruiting

Leukemia, Chronic Trials at a Glance

11 actively recruiting trials for leukemia, chronic are listed on ClinicalTrialsFinder across 6 cities in 22 countries. The largest study group is Phase 2 with 5 trials, with the heaviest enrollment activity in Milan, Madrid, and Istanbul. Lead sponsors running leukemia, chronic studies include Catapult Therapeutics, European Institute of Oncology, and Augusta University.

Browse leukemia, chronic trials by phase

Treatments under study

About Leukemia, Chronic Clinical Trials

Looking for clinical trials for Leukemia, Chronic? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Leukemia, Chronic trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Leukemia, Chronic clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 111 of 11 trials

Recruiting

Cohort of Patients With Chronic Myelomonocytic Leukemia

LeukemiaMyelomonocytic Leukemia, Chronic
Gustave Roussy, Cancer Campus, Grand Paris5,000 enrolled24 locationsNCT07512882
Recruiting
Phase 2

A Study of Treatment-free Remission in Chronic Phase Chronic Myeloid Leukemia

Chronic Myeloid Leukemia, Chronic Phase
Korean Society of Hematology69 enrolled1 locationNCT06368414
Recruiting
Phase 2

Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase

Leukemia, MyeloidChronic Myeloid Leukemia, Chronic PhaseLeukemia,Myeloid, Chronic+1 more
Augusta University100 enrolled7 locationsNCT05143840
Recruiting
Phase 3

A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).

CLLLeukemia, Lymphocytic, Chronic, B-CellLymphoma, Small Lymphocytic+3 more
Merck Sharp & Dohme LLC735 enrolled52 locationsNCT05947851
Recruiting
Phase 1Phase 2

Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias

Acute Lymphoblastic LeukemiaSmall Lymphocytic LymphomaLymphoblastic Lymphoma+4 more
National Cancer Institute (NCI)132 enrolled1 locationNCT06364423
Recruiting
Phase 1Phase 2

A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL)

Chronic Myeloid LeukemiaChronic Myeloid Leukemia, Chronic Phase
Terns, Inc.180 enrolled54 locationsNCT06163430
Recruiting
Phase 1

CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia

SLLLymphocytic Leukemia, Chronic
Catapult Therapeutics18 enrolled4 locationsNCT04704323
Recruiting
Phase 2

PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML

Chronic Myeloid LeukemiaChronic Myeloid Leukemia, Chronic PhaseCML, Chronic Phase+1 more
Gruppo Italiano Malattie EMatologiche dell'Adulto160 enrolled11 locationsNCT06409936
Recruiting

Ponatinib in Chronic Myeloid Leukemia Patients in Chronic Phase

Chronic Myeloid Leukemia, Chronic Phase
University of Pisa100 enrolled5 locationsNCT06119269
Recruiting
Phase 3

A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs

Chronic Myeloid Leukemia, Chronic PhaseCML, Chronic PhaseCML, Refractory+1 more
Il-Yang Pharm. Co., Ltd.173 enrolled18 locationsNCT03459534
Recruiting

Total Body Irradiation Treatments for Patients Treated at European Institute of Oncology

LymphomaLeukemiaLeukemia, Chronic+2 more
European Institute of Oncology50 enrolled1 locationNCT06335277